GLP-1 drugs move beyond diabetes and weight loss to multi-organ protection Experts emphasised that while weight loss remains central, the real impact lies in reducing harmful fat deposits and improving organ function over time
Patients managing chronic conditions with elevated oxidative load may experience symptom re-emergence 23 weeks after stopping, but this reflects the underlying pathology, not a withdrawal effect
Obesity (Silver Spring) 2023;31:35062.PubMedPMC 44
writingoriginal draft preparation, S.S
In a study by Omori et al
CrossRef Myeloid KIF13B suppresses the STT3A/CTSD/THBS1 axis to prevent MASH Kaikai Lu, Xianqin Shen, Ziyang Guo, Jingxuan Chen, Lei He, Aiden Xian, Si Mei, Yufei Han, Yinqi Zhao, Jinxuan Chen, Sijing Shi, Guolin Miao, Yitong Xu, Zihao Zhou, Lianxin Zhang, Chao Zhai, Ziwei Wang, Ling Zhang, Minghua Zheng, Lin Yao, Wei Huang, Yuhui Hepatology .2026;[Epub] CrossRef Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study Yue Li, Zixian Li, Siyu Wu, Ling Cao, Beibei Qian, Junxian Tao, Zhimin Qian, Li Xie, Xiaoli Cai, Xiaofang Sun, Ying Li, Zhenwen Zhang, Caifeng Yan, Dunmin She BMC Endocrine Disorders .2026;[Epub] CrossRef Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights Marina Idalia Rojo-Lpez, Julia Nio-Narvin, Maria Antentas, Berta Fernndez-Camins, Elizabeth Martnez-Rojo, Maria Poca, Mara Antonia Martnez-Snchez, Bruno Ramos-Molina, Joana Rossell, Didac Mauricio, Josep Julve Nutrients .2026
